Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologiesbla_glas_labb

 

Tripep AB has reached an agreement regarding shared development of Tripep's wound healing project, ChronSeal, with the Japanese company Kringle Pharma, a world leading company in the development of the growth factor HGF (Hepatocyte Growth Factor). 

The company has received final approval to start a clinical study of ChronVac-C® on patients with a chronic infection of Hepatitis C virus.



CEO Statement

After intensive efforts on our turnaround, we now have a company in...

>> CEO Statement.(pdf)

Latest Reports

2010-01-29
>> Year-end Report 2009
2009-10-23
>> Interim Report January-September 2009


 

 

Latest press releases

>> More press releases
>> Subscribe